Pulse Sequence for Positive Contrast in MRI CEST (BIDMC 1180)

Category:    Software/Algorithms

KeyWords:  Method;  Bioinformatics/Informatics;  

BIDMC ID:    1180

Abstract:

Conventional MRI CEST monitors signals detected after applying RF radiation at two different frequencies, RF-OFF and RF-ON. The RF-OFF signal is reference, while the RF-ON is selected to match an excitation frequency of the exchanging groups of molecules of interest. The subsequent suppression of the signal of these groups using RF-ON has the effect of decreasing the image signal. The contrast thus generated is small and negative. Molecules of interest are followed as the difference between the control signal and the lesser signal obtained using RF-ON. The difference between the two signals is small compared to the signals themselves, giving low signal-to-noise. BIDMC’s Vinogradov & Lenkinski use a new RF pulse sequence that flips the contrast such that the signal obtained using RF-ON is greater than the control signal. When timed right, this difference is measured as a positive contrast when the control signal is nearly zero, providing increased sensitivity and decreased background artifacts. This invention enables new MRI CEST software using a method that combines a novel pulse sequence with a specific timing schedule for detection. Software to control such methods may be used on standard MRI imaging hardware without modification. MARKET: *Radiologists seeking higher contrast CEST and PARACEST images * Applications monitoring: —Low levels of contrast agent —Small changes in the environments of -OH or –NH exchanging groups

Inventor:   Elena Vinogradov, PhD Robert Lenkinski, PhD

Commercial Opportunity:

* Method patent for pulse sequence and detection schedule * Flexible licensing options

Competitive Advantages:

* Improved SNR and image clarity * Cross-platform MRI CEST functionality

Related Publications:

State of Development:

Validated proof-of-concept with phantoms and animals
Clinical testing to begin 2009

Related Technology URL:

http://research.bidmc.harvard.edu/research/ResearchPIInfo.ASP?Submit=Display&PersonID=863

Patent Status:

Patent Pending

TVO Contact Info:
     Jason S Felsch
     Senior Licensing Manager, TVO
     jfelsch@bidmc.harvard.edu
     Phone: 617-667-9490   Fax: 617-667-0646

     Beth Israel Deaconess Medical Center
     Technology Ventures Office  Room: BR-202
     330 Brookline Avenue
     Boston, MA 02215